Kornimate/medical-research-clean huggingface dataset:
a multicenter phase ii trial of post-operative concurrent chemoradiotherapy using weekly cisplatin with tislelizumab for patients with high-risk head and neck squamous cell carcinoma：the potential study

Conditions: Head and Neck Cancer; Radiation; PD-1

Summary: to investigate whether concurrent tislelizumab with postoperative chemoradiotherapy would have survival benefit in high risk hnscc patients.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed squamous cell carcinoma of the head and neck. site of tumor origin in the oral cavity, oropharynx (p16-), larynx, or hypopharynx 2. with at least one high risk factor after radical surgery ①positive margin; ②close margin（\<5mm); ③ene. 3. no distant metastases 4. no synchronous or concurrent head and neck primary tumors 5. ecog ps 0-1 6. adequate organ function including the following: absolute neutrophil count (anc) \>= 1.5 \* 10\^9/l platelets count \>= 80 \* 10\^9/l hemoglobin \>= 80 g/dl ast and alt \ 30 ml/min 8. signed written informed consent exclusion criteria: 1. prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior radiotherapy to the head and neck region 2. other previous cancer, except for in situ cervical cancer and cutaneous basal cell carcinoma 3. pregnant or breast-feeding females, or females and males of childbearing potential not taking adequate contraceptive measures 4. uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia 5. active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, crohn's disease, autoimmune thyroiditis. subjects with cured childhood asthma, type i diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment 6. using systemic immunosuppressive agents and continue the dose within 2 weeks prior to the enrollment;
age-related differences in shoulder dynamic and isometric contractions

Conditions: Electromyography

Summary: a cross-sectional descriptive study, in which the surface electromyographic activity of five shoulder muscles was compared in two populations: older adults and adults. the evaluation of the electromyographic data offers a suitable foundation to understand aging process. this supports that surface electromyography provide information about the aged shoulder muscles. loss of functionality is suffered by a high percentage of older adults, which greatly limits their physical activity. in this sense, this paper presents findings that might be related with possible therapeutic approaches in subsequent studies.

aging processes in the musculoskeletal system lead to functional impairments that restrict participation. purpose: to assess differences in force and motor recruitment patterns of shoulder muscles between age groups to understand functional disorders. a cross-sectional study comparing thirty adults (20-64) and 30 older adults (\>65). surface-electromyography (semg) of the middle deltoid, upper and lower trapezius, infraspinatus and serratus anterior muscles was recorded. maximum isometric voluntary contraction (mivc) was determined at 45° glenohumeral abduction. for the semg signal registration, concentric and excentric contraction with and without 1 kg and isometric contraction were requested. participants abducted the arm from 0° up to an abduction angle of 135° for concentric and excentric contraction; and from 0º to 45º and remained there at 80% of the mivc level while isometrically pushing against a handheld dynamometer. differences in semg amplitudes (root mean square, rms) of all contractions, but also onset latencies during concentric contraction of each muscle between age groups were analyzed. statistical differences in strength (adults\>older adults;0.05) existed between groups. no significant differences in rms values of dynamic contractions were detected, except for serratus anterior, but there were for isometric contraction of all muscles analyzed (adults\>older adults;0.05). the recruitment order varied between age groups, showing a general tendency towards delayed onset times in older adults, except for the upper trapezius muscle. age differences in muscle recruitment patterns were found, which underscores the importance of developing musculoskeletal data to prevent and guide geriatric shoulder pathologies.

Eligibility criteria:
inclusion criteria: * healthy subjects * no previously manifested symptoms in the shoulder joint and/or the neck during the past year, exclusion criteria: * moderate or severe cognitive impairment * rheumatologic diseases * massive osteoarthritis * tumors * shoulder joint instability * circulatory disorders (hemophilia clotting problems) * dermatological problems exacerbated by contact with skin.

Keywords: age groups shoulder muscles musculoskeletal diseases
heart rate variability as a clinical marker in a population of anxio-depressive patients

Conditions: Anxio Depressive Disorder

Summary: the heart rate (hr) is regulated by the autonomic nervous system (ans) and results from a balance between the sympathetic nervous system (sns) that accelerates the heart rate and the parasympathetic nervous system that slows the hr via the vagus nerve. low hrv is linked to poor emotional and cognitive regulation. values for hrv are generally lower in depressed patients. the aim of this study is to determine how hrv could be a clinical marker that can be used in routine psychiatry practice in patients with anxio-depressive disorders, to determine the severity of symptoms and the degree of response to treatment.


Eligibility criteria:
inclusion criteria: - patients of the chu brugmann hospital with an anxious or depressive disorder exclusion criteria: - none
nitrous oxide as a putative novel dual-mechanism treatment for bipolar disorder

Conditions: Bipolar Disorder

Summary: this study is a 7-day randomized, double-blind proof-of-concept pilot study of nitrous oxide vs. midazolam in 40 adults (20-60 years) with bipolar disorder (bd) (type i or ii). ongoing pharmacological and psychosocial treatments may continue, provided that they have not been initiated or significantly modified in the preceding 2 weeks. participants' current treatment as prescribed by clinical psychiatrists will not be modified or interfered in this study. the study involves 3 visits. during study visit 1, participants will complete screening to ensure study eligibility. this will be done using interview measures. during study visit 2, participants will complete anthropomorphic measurements, measurement of endothelial function, screening blood work, ecgs, and an anaesthesia screener. during study visit 3, participants will receive the treatment (nitrous oxide or midazolam), complete an mri scan, and complete interview measures and self-reports. there will be anthropomorphic measurements taken as well. the participant will be required to complete phone interviews and self-reports over the subsequent 7 days. there are 4 main predictions: 1. nitrous oxide will significantly reduce depression symptoms vs. midazolam. 2. nitrous oxide will significantly increase frontal cortical perfusion vs. midazolam. 3. lower perfusion in frontal cortical regions at baseline will be associated with greater improvement in depression symptoms following nitrous oxide treatment. 4. poorer endothelial function will be associated with greater improvement in depression symptoms following nitrous oxide treatment.


Eligibility criteria:
inclusion criteria: english-speaking; age 20-60 years; bd-i or bd-ii, current major depressive episode ≥4 weeks duration; madrs≥22; taking ≥1 mood stabilizing medication/s (i.e. antimanic anticonvulsant, antipsychotic, and/or lithium). exclusion criteria: new medications or changes in dosing, or ect or tms, in the preceding 2 weeks; madrs item 10, \> 4; ymrs≥12; acute significant suicidality; psychosis; substance abuse (past 3 months); active major medical conditions (hepatic, renal, respiratory, or cardio/cerebrovascular disease; diabetes; esophageal reflux; sleep apnea); b12 deficiency/disorders; pregnant; mri contraindications; history of adverse anaesthetic reactions; anaesthesia class \>2; scuba diving in preceding week.
use of alternative and complementary medicine by colorectal cancer patients

Conditions: Colorectal Cancer

Summary: complementary and alternative medicine (cam) is defined by the national center for complementary and alternative medicine as "a group of diverse medical and health systems, practices and products that are not currently considered part of conventional medicine" (complementary, alternative, or integrative health, n. d. 2012). complementary medicine is used to complement conventional medicine, and alternative medicine is used instead of conventional medicine (dy et al., 2004). these are two very different approaches, whose consequences for a cancer patient can be completely different. the use of cam is steadily increasing in most countries. a study carried out in france in 2017 revealed that for half of cam users, the diagnosis of cancer was one of the main factors that led patients to turn to cam (sarradon-eck et al., 2017). cam use was found to be significantly associated with younger age, female gender and higher education (sarradon-eck et al., 2017). the source of information about mac was mainly friends/family and the media, while doctors and nurses played a succinct role in mac information (molassiotis et al., 2005). the most frequently cited reasons for using cam were to improve their physical well-being, strengthen their bodies, improve their emotional well-being and relieve the side effects of treatment (sarradon-eck et al., 2020). another study carried out in 2019 at nine centers in france showed that 45% of glioma patients had changed their eating habits after glioma diagnosis, 44% were on complementary treatment, mainly vitamins and dietary supplements, and 32% were using alternative medicine, mainly magnetism and acupuncture. a total of 68% reported using at least one of these approaches (le rhun et al., 2019). another single-center study conducted in france in 2019 found that 83% of cancer patients used cam (m et al., 2019). cam included osteopathy, homeopathy, acupuncture, therapeutic touch, magnetism, naturopathy, cupping, chinese medicine, reflexology and hypnosis. however, no studies have been carried out to assess the use of cam among colorectal cancer (crc) patients in france.


Eligibility criteria:
inclusion criteria: * over 18 years of age * diagnosed with colorectal cancer * to be operated on between 2017 and 2022 exclusion criteria: * the patient refuses to give consent to participate in the study * non-primary colorectal cancer (metastasis to the colon or rectum from another primary cancer; cancer originating in the appendix) * primary metastatic cancer other than colorectal cancer * discovery of cancer synchronous with colorectal cancer * guardianship or trusteeship * cognitive disorders (alzheimer's, dementia, etc.) * severe psychiatric disorder (neurodevelopmental disorder, psychotic disorder, mood disorder, etc.) according to the specific dsm-5 and icd-11 classifications * severe deafness (unable to answer questions during telephone interview)

Keywords: colorectal cancer complementary and alternative medicine
triple therapy in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: the treatment of type 2 diabetes mellitus often requires the use of one or more hypoglycemic agents to reach the adequate glycemic control. the aim of the study is to evaluate the effects of a triple therapy with metformin, pioglitazone and sitagliptin on glycemic variability compared to metformin monotherapy, and compared to a combination of metformin and pioglitazone. to assess glycemic variability a continuous glucose monitoring system will be used.

in an estimated temporal space of about 3 years, 64 not well controlled, type 2 diabetic patients will be recruited. patients will be instructed to take metformin 500 mg three times a day for the first three months, then pioglitazone 15 mg twice a day will be added for further three months, and finally sitagliptin 100 mg once a day will be added for the last three months. at the baseline, and every three months a continuous glucose monitoring system will be performed. at any stage of the study, if the value of glycated hemoglobin reach the desired goal (\<6.5%), participation in the study will be stopped and the patient will not be subjected to further adjustments of hypoglycemic therapy or additional continuous monitoring glucose. after collection of written informed consent, the following data will be collected: * history: type of diabetes, comorbidities, current medication, duration of diabetes and complications, voluptuary habits such as tobacco smoke (both number of packets/year and n° packets/day), alcohol consumption, coffee consumption, physical activity. * physical exam, general anthropometric parameters such as weight, height, circumference, body mass index, waist-hip ratio, and blood pressure. * assessment of glycemic variability every three months using a continuous glucose monitoring system. * collection of blood and urine samples to assess: glycated hemoglobin, fasting plasma glucose (fpg), post-prandial glucose (ppg), fasting plasma insulin (fpi), homa-index (homa-ir and homa-β), high sensitivity c-reactive protein (hs-crp), total cholesterol, ldl-cholesterol, hdl-cholesterol, tryglicerides, lipoprotein (a) \[lp(a)\], metalloproteinase-2 (mmp-2), metalloproteinase-9 (mmp-9), soluble adhesion molecules (sicam-1, svcam-1), se-selectin, adiponectin (adn), complete urinalysis, 24-hour microalbuminuria.

Eligibility criteria:
inclusion criteria: * type 2 diabetic patients * naive to therapy * glycated hemoglobin \> 6.5 and \< 9.0 % exclusion criteria: * hepatic and renal diseases * recent cardiovascular diseases * previous pancreatitis * history of cancer
renal artery calcium and hypertension

Conditions: Hypertension; Atherosclerosis

Summary: ct of the abdomen is a very common examination performed for various indications.one of the common findings is vascular calcifications including calcifications of the renal arteries.calcifications in the carotid arteries and coronary arteries are good predictor for obstructive atherosclerotic disease.stenosis of the renal arteries can cause symptomatic or asymptomatic hypertension with subsequent clinical sequelae. therefore early diagnosis of this condition is imperative. the goal of our study is to investigate the correlation between incidental calcifications of the renal arteries in ct examinations and the presence of actual stenosis of these vessels in patients with and without hypertension.

every patient aged 30-100 referred for abdominal ct examination with iv contrast injection will be included in this study (total 300 patients.prior to the examination relevant clinical data including history of hypertension and predisposing conditions for atherosclerotic disease, will be investigated. the patient will undergo conventional ct with no special procedures. the images will be review by the radiologist for the presence of renal arteries calcifications, renal arteries stenosis,plaque location, plaque burden and characterization and secondary renal pathology. this study will not change the examination technique and is not associated with any inconvenience to the patients.

Eligibility criteria:
inclusion criteria: * every patient referred fo abdominal ct aged 30-100 exclusion criteria: * contraindication for iv contrast injection failure to demonstrate renal arteries with contrast refusal to sign an informed consent

Keywords: renal artery calcium ct hypertension
pet study of the nicotinic system in epilepsy

Conditions: Epilepsy

Summary: mutations in neuronal nicotinic acetylcholine receptors (nachrs) have been identified in the autosomal dominant nocturnal frontal lobe epilepsy (adnfle). despite the demonstration of a gain of function of the mutated receptors, the precise mechanisms leading to this nocturnal epilepsy are still unknown. in 2006 the investigators studied the nachr cerebral distribution in a group of patients with adnfle carrying a nachr mutation, by a pet-scan using \[18f\]-f-a-85380, a ligand with a high affinity and specificity for alpha4beta2 nicotinic receptors. the study showed a different pattern of brain distribution of the radiotracer in the adnfle patients when compared to a group of control subjects, with a significant increase of nicotinic receptor density in the patients in mesencephalon and cerebellum (picard et al., brain 2006). based on the known biochemical and cellular circuits in the brainstem, these results suggest that the nachr density increase in mesencephalon is involved in the pathophysiology of adnfle through the role of brainstem ascending cholinergic systems in arousal. the follow-up step consists of extending this examination to other forms of epilepsy, in order to verify the specificity of the hyperfixation pattern for adnfle, and search for a potential involvement of nicotinic receptors in other forms of epilepsy. the investigators aim to study 5 groups of subjects: control subjects (group 1, 20 subjects); patients with a non lesional partial epilepsy and a predominance of diurnal seizures (group 2, 12 subjects); patients with an idiopathic generalized epilepsy (group 3, 12 subjects); patients with nocturnal frontal lobe epilepsy (group 4, 3 subjects) and epileptic patients with vagal nerve stimulation (group 5, 1 subject). for each patient, a cerebral mri, \[18f\]- fluorodeoxyglucose (fdg) pet/ct and \[18f\]-f-a-85380 pet/ct examinations are planned. the investigators will perform data analyses on volume of distribution (vt) parametric images which will be based on the ratio of brain tissue to unchanged f-a-85380 plasma at equilibrium. statistical parametric mapping (spm2) will be used to further study the parametric pet images. this study is primarily dedicated to demonstrate that the pattern of hyperfixation that was obtained in adnfle patients is specific for this disorder and does not constitute a common pattern to various forms of epilepsy. the investigators will also search for a possible involvement of the nachrs in other forms of epilepsy.


Eligibility criteria:
inclusion criteria: * males * 18-60 years old * non-smokers exclusion criteria: * smoking during the past twelve months * contraindications to mri * brain lesions on mri (including hippocampal atrophy) * neurological disorder (other than epilepsy) or psychiatric disorder * neoplasia or coronary disease * blood test showing : creatinine clearance \ 2 x upper standard, or gamma-gt \> 3 x upper standard, or albumin \ 48 g/l . * patients only : nuclear imaging during the past twelve months * healthy volunteers only : ionising radiation exam during the past five years
heart rate changes in subjects with epilepsy

Conditions: Epilepsy

Summary: the purpose of this study is to collect continuous observational data during a clinical epilepsy monitoring unit evaluation.

observational, unblinded, non-randomized, multisite study designed to collect data on up to 500 subjects undergoing evaluation for epilepsy in emus. subjects currently enrolled or that previously participated in this study may be eligible for the e-30-s sub-study.

Eligibility criteria:
inclusion criteria: patients enrolled in the study must meet all of the following criteria: 1. patient has a clinical diagnosis of epilepsy requiring evaluation in an epilepsy monitoring unit (emu). 2. patient likely requires an emu evaluation for a period of at least 24 hours. 3. patient is currently taking at least one antiepileptic medication. 4. patient must be in good general health and fully ambulatory. 5. patient or guardian must be willing and able to complete informed consent/assent and hipaa authorization. exclusion criteria: patients who meet any of the following criteria are not eligible to be enrolled in the study: 1. patients with severe psychiatric disease that in the investigator's judgment would prevent the patient's successful completion of the study. 2. patients with a history of status epilepticus. 3. patients prescribed drugs specifically for a cardiac or autonomic disorder that in the investigator's opinion would affect heart rate response. drugs with secondary cardiac or autonomic actions are allowed. 4. patients with cardiovascular arrhythmias or cardiac disease that would preclude the ability to detect intrinsic changes in heart rate due to exercise, stress, or seizure. this would include but not be limited to chronic atrial fibrillation, chronotropic incompetence, and permanent cardiac pacemaker implantation. 5. patients with a history of dependence on alcohol or narcotic drugs within the past 2 years as defined by dsm iv-r.
measurement of the diaphragm loading during the training with a imt device

Conditions: Sports Physical Therapy

Summary: it is well known that the the training with the imt device increases the maximal inspiratory pressure. nonetheless, there are doubts about which muscles are involved during this training. the aim of this study is to determine the diaphragm loading of healthy subjects during the training with a imt device from a low . therefore, each subject will be monitored using esophageal and gastric manometry.

this study has a quasi-experimental design. the investigators will recruit ten healthy adult volunteers without anticoagulation or esophageal lesions, after signing a consent form. after checking the appropriate correct position of each catheter, each subject will use the imt device throughout different randomized loads (percentages of the maximal inspiratory pressure, counting by tens from 10% to 100%). fluxmed® grt mbmed respiratory mechanic monitor will be used. each percentage of resistive load will be maintained for 5 inspirations. meanwhile, an operator will register the esophageal pressure,the gastric pressure and the transdiaphragmatic pressure. diaphragm collaboration in each percentage of resistive load will be determine by calculating the relation between the gastric pressure and the transdiaphragmatic pressure (∆pgas/∆pdi).

Eligibility criteria:
inclusion criteria: * older than 18 years * healthy subjects exclusion criteria: * without anticoagulation * without esophageal lesions * without airway lesions * without spirometry alterations
response of topical capsaicin in alopecia areata

Conditions: Alopecia Areata

Summary: it has been postulated that alopecia areata (aa) is, at least in part, a neurologically mediated disease. research supporting this theory includes the finding that nerves surrounding the hair follicles are collapsed. we want to take this research a step further and show that not only are these perifollicular nerves collapsed, but that their function is also impaired.

to assess the function of perifollicular scalp nerves in aa we will look at the response of these nerves to the topical medication capsaicin. under normal circumstances topical capsaicin is known to target nerves in the peripheral nervous system causing short-term release of the neuropeptide substance p (sp) as well as long-term transient depletion of sp. we expect the aa patients will respond abnormally to topical capsaicin treatment.

Eligibility criteria:
inclusion criteria: * must have alopecia totalis or universalis. * be in good health. * not be taking any medications including topical medications * be 18 years or older. * be willing to apply study medication or vehicle as directed, comply with instructions and commit to follow-up visits. * not have had hair chemically treated (including colored hair, permed hair, etc) within the month prior to the study. exclusion criteria: * absence of extensive alopecia areata. * people not in good health. * people taking medications. * allergies to capsaicin. * presence of irritated or visibly inflamed scalp. * having had hair chemically treated (including colored hair, permed hair, etc.) within the month prior to study.